Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566760 | 0.85 | PTGER1 (0.47) | PTGER1TBXA2RL3MBTL1MCL1BRD4 | |
| SCHEMBL7489203 | 0.84 | PTGER1 (0.47) | PTGER1TBXA2RL3MBTL1BRD4 | |
| SCHEMBL6604823 | 0.83 | PTGS1 (0.55) | PTGER1TBXA2RMCL1RXRARXRB | |
| SCHEMBL6605630 | 0.81 | PTGER1 (0.48) | PTGER1TBXA2RMCL1BRD4RXRA | |
| SCHEMBL6604669 | 0.81 | RXRA (0.62) | PTGER1TBXA2RMCL1RXRARXRB | |
| SCHEMBL6604924 | 0.80 | PTGER1 (0.62) | PTGER1TBXA2RMCL1RXRARXRB | |
| SCHEMBL6191978 | 0.75 | PTGER1 (0.80) | PTGER1TBXA2R | |
| SCHEMBL5107180 | 0.73 | PTGER1 (0.64) | PTGER1TBXA2R | |
| SCHEMBL6605970 | 0.71 | RXRA (0.66) | PTGER1TBXA2RMCL1RXRARXRB | |
| SCHEMBL26013299 | 0.70 | MAPT (0.63) | PTGER1L3MBTL1MCL1BRD4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216238-B1 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA INC (CA) | 2004-02-18 | — | — | EP | claimed |
| EP-1216238-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Frosst Canada & Co. (CA) | 2002-06-26 | — | — | EP | claimed |
| US-6369084-B1 | PROSTAGLANDIN MEDIATED DISEASES | MERCK FROSST CANADA & CO. (CA) | 2002-04-09 | — | — | US | claimed |
| WO-2001019814-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 2001-03-22 | — | — | WO | claimed |
| EP-1216238-B1 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA INC (CA) | 2004-02-18 | — | — | EP | disclosed |
| US-20020137746-A1 | Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists | CARL FRANCOIS JOSEPH (CA) | 2002-09-26 | — | — | US | disclosed |
| EP-1216238-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Frosst Canada & Co. (CA) | 2002-06-26 | — | — | EP | disclosed |
| US-6369084-B1 | PROSTAGLANDIN MEDIATED DISEASES | MERCK FROSST CANADA & CO. (CA) | 2002-04-09 | — | — | US | disclosed |
| WO-2001019814-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137746-A1 | Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists | PTGER1, PTGIR, PTGS1 | PTGER1 1/4885TBXA2R 20/4885RAB9A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.